verified SJR 2,779 · Q1 • database Scopus / SJR & Web of Science indexed

Switzerland · S. Karger AG

workspace_premium Q1 — Oncology lock Subscription

Liver Cancer

Liver Cancer is a journal indexed in SJR in Oncology and Hepatology with an H index of 63. It has an SJR impact factor of 2,779 and it has a best quartile of Q1. It has an SJR impact factor of 2,779.

ISSN: 2235-1795

Publisher: S. Karger AG

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

2,779 Q1

H-index 63

Acceptance rate pie_chart

32%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

2,779

H-index

Docs (year)

Docs 3y

174

Total refs

2554

Cites 3y

1492

Citable 3y

146

Cites/Doc 2y

7.12

Ref/Doc

42.57

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis

Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy

Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma

Waist Circumference and Risk of Liver Cancer: A Systematic Review and Meta-Analysis of over 2 Million Cohort Study Participants

Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?

Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis

Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review

Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies

Reply to the Letter to the Editor Entitled "Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?"

Recent Progress in the Treatment and Diagnosis of Hepatocellular Carcinoma

Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma

Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial

SHOW MORE ARTICLES

Rescue Living-donor Liver Transplantation for Liver Failure Following Hepatectomy for Hepatocellular Carcinoma

Preoperative Low Muscle Mass and Low Muscle Quality Negatively Impact on Pulmonary Function in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma

Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib

Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection

Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment

Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma

Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment

Methodological Limitations to the Analysis by Cicalese et al.

Mean Platelet Volume and Unresectable Hepatocellular Carcinoma

Management of Hepatocellular Carcinoma in Japan: Current Trends

Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status

FAQs

Liver Cancer has an SJR of 2,779 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Liver Cancer is 32%.

Liver Cancer

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Liver Cancer?

What is the APC / publication cost?

What is the acceptance rate?